Guangdong Hybribio Biotech Co.,Ltd.

Equities

300639

CNE100002N51

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
6.2 CNY +2.31% Intraday chart for Guangdong Hybribio Biotech Co.,Ltd. +1.47% -33.62%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023 CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
Guangdong Hybribio Biotech, Subsidiary Get Patent from Brazil for Isolation Method MT
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System MT
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares. CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan. CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Two Guangdong Hybribio Biotech Units Get Licenses from Drug Regulator MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangdong Hybribio Biotech Registers Gene Testing Kit MT
Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023 CI
Hybribio Biotech Appoints Chief Medical Officer MT
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022. CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on October 26, 2022 has closed with 5,937,000 shares, representing 0.91% for CNY 100 million. CI
Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023 CI
Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for 2022 CI
Hybribio Biotech Patents HPV Gel in Indonesia MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022. CI
Guangdong Hybribio Biotech Registers Gene Testing Device MT
Hybribio Biotech Patents Chloroquine Phosphate Gel in Europe MT
Chart Guangdong Hybribio Biotech Co.,Ltd.
More charts
Guangdong Hybribio Biotech Co Ltd is a company mainly engaged in production and sales of vitro diagnostic reagents. The Company operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.2
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300639 Stock
  4. News Guangdong Hybribio Biotech Co.,Ltd.
  5. Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System